Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells

Busulfan (Bu) is a bifunctional DNA-alkylating agent commonly used in combination with other agents for high-dose pretransplantation conditioning therapy for hematopoietic stem cell transplantation (HSCT) [1]. Its combination with cyclophosphamide (Cy) has been used as an alternative to a Cy plus total body irradiation (Cy+TBI)-containing myeloablative regimen and found to be effective for acute leukemias [2 –7]. The “BuCy2” preparative regimen is more effective than Cy+TBI in patients ≤40 years old [6,8].

Source: Experimental Hematology - August 10, 2018 Category: Hematology Authors: Benigno C. Valdez, Xiaowen Tang, Yang Li, David Murray, Yan Liu, Uday Popat, Richard E. Champlin, Borje S. Andersson Source Type: research